ong-term impact of eculizumab on quality of life and patient-reported symptoms of Japanese GBS patients at 52 weeks post disease onset: an observational survey
Not Applicable
- Conditions
- Guillain-Barre syndrome
- Registration Number
- JPRN-UMIN000048078
- Lead Sponsor
- Alexion Pharma G.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 99
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are unable to answer the study questionnaires and who do not have any next of kin or caregiver available to answer the study questionnaire on their behalf
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Short Form McGill Pain Questionnaire 2 (SF-MPQ-2) DASS: Depression Anxiety Stress Scale (DASS-21) EuroQoL- 5 Dimension 5 Level (EQ-5D-5L)
- Secondary Outcome Measures
Name Time Method